BACKGROUND: This study examined the influence of prior treatment on the course of cognitive functioning in breast cancer survivors. Changes in cognitive functioning over time were compared in breast cancer survivors treated with chemotherapy plus radiotherapy, breast cancer survivors treated with radiotherapy only, and women with no history of cancer. METHODS: Stage 0-II breast cancer patients treated with chemotherapy plus radiotherapy (CT group; n = 62) or radiotherapy only (RT group; n = 67) completed neuropsychological assessments 6 months after completing treatment and again 36 months later. Women with no history of cancer (NC group; n = 184) were assessed over a similar interval. RESULTS: A significant group × time effect was found for processing speed (P = .009) that reflected a tendency for the NC group but not the RT and CT groups to improve over time. There was also a significant group effect for executive functioning (P = .006) that reflected the NC group performing better than the CT and RT groups. Additional analyses found the administration of hormonal therapy was not associated with change over time in cognitive performance. CONCLUSIONS: Findings provide limited support for the view that changes in cognitive functioning in cancer survivors are attributable to chemotherapy administration and illustrate the importance of including a radiotherapy comparison group. Future research should seek to examine possible mechanisms that could explain the apparent prolonged impact of both chemotherapy and radiotherapy on cognitive functioning in breast cancer survivors.
BACKGROUND: This study examined the influence of prior treatment on the course of cognitive functioning in breast cancer survivors. Changes in cognitive functioning over time were compared in breast cancer survivors treated with chemotherapy plus radiotherapy, breast cancer survivors treated with radiotherapy only, and women with no history of cancer. METHODS: Stage 0-II breast cancerpatients treated with chemotherapy plus radiotherapy (CT group; n = 62) or radiotherapy only (RT group; n = 67) completed neuropsychological assessments 6 months after completing treatment and again 36 months later. Women with no history of cancer (NC group; n = 184) were assessed over a similar interval. RESULTS: A significant group × time effect was found for processing speed (P = .009) that reflected a tendency for the NC group but not the RT and CT groups to improve over time. There was also a significant group effect for executive functioning (P = .006) that reflected the NC group performing better than the CT and RT groups. Additional analyses found the administration of hormonal therapy was not associated with change over time in cognitive performance. CONCLUSIONS: Findings provide limited support for the view that changes in cognitive functioning in cancer survivors are attributable to chemotherapy administration and illustrate the importance of including a radiotherapy comparison group. Future research should seek to examine possible mechanisms that could explain the apparent prolonged impact of both chemotherapy and radiotherapy on cognitive functioning in breast cancer survivors.
Authors: Christina M Schilder; Caroline Seynaeve; Louk V Beex; Willem Boogerd; Sabine C Linn; Chad M Gundy; Hilde M Huizenga; Johan W Nortier; Cornelis J van de Velde; Frits S van Dam; Sanne B Schagen Journal: J Clin Oncol Date: 2010-02-08 Impact factor: 44.544
Authors: Heather S L Jim; Kristine A Donovan; Brent J Small; Michael A Andrykowski; Pamela N Munster; Paul B Jacobsen Journal: Cancer Date: 2009-04-15 Impact factor: 6.860
Authors: S B Schagen; M J Muller; W Boogerd; R M Rosenbrand; D van Rhijn; S Rodenhuis; F S A M van Dam Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Yuelin Li; Charlotte T Furstenberg; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Theresa Crowgey; Katherine B Peters; Whitney E Hornsby; Amy Lane; Frances McSherry; James E Herndon; Miranda J West; Christina L Williams; Lee W Jones Journal: Appl Physiol Nutr Metab Date: 2013-12-03 Impact factor: 2.665
Authors: Victoria A Shaffer; Edgar C Merkle; Angela Fagerlin; Jennifer J Griggs; Kenneth M Langa; Theodore J Iwashyna Journal: Med Care Date: 2012-10 Impact factor: 2.983
Authors: Shelli R Kesler; Jeffrey S Wefel; S M Hadi Hosseini; Maria Cheung; Christa L Watson; Fumiko Hoeft Journal: Proc Natl Acad Sci U S A Date: 2013-06-24 Impact factor: 11.205
Authors: Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-07 Impact factor: 11.908
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Juan Antonio Cruzado; Sonia López-Santiago; Virginia Martínez-Marín; Gema José-Moreno; Ana Belén Custodio; Jaime Feliu Journal: Support Care Cancer Date: 2014-02-18 Impact factor: 3.603